Analysis of the value and safety of thyroid-stimulating hormone in the clinical efficacy of patients with thyroid cancer

Table 3 Comparison of free triiodothyronine and free tetraiodothyronine levels in each group (mean ± SD)

Group	FT3 (ng/L)		FT4 (ng/L)
	Before treatment	After treatment	Before treatment	After treatment
Control (n = 50)	1.54 ± 0.23	2.23 ± 1.62	0.50 ± 0.16	0.89 ± 0.82
Observation (n = 75)	1.58 ± 0.27	3.12 ± 1.65	0.48 ± 0.11	1.56 ± 1.48
t	0.860	2.976	0.829	2.914
P value	0.392	0.004	0.409	0.004

FT₃: Free triiodothyronine; FT₄: Free tetraiodothyronine.